Pharmacokinetics
To assess plasma concentrations of WNT974, its active metabolite LHA333, and encorafenib, serial blood samples were collected on days 1 and 15 of cycle 1, and pre-dose blood samples were collected on days 2, 8, 16, and 22 of cycle 1, and on day 1 of cycles 2, 3, and 4. PK parameters were determined using noncompartmental methods. The PK analysis set included all patients with at least one available valid PK concentration measurement who received at least one dose of study drug.